EASL Studio Podcast: Rethinking Hepatitis B: Discussions with Patients – Adapting to Expanding Treatment Guidelines

This episode addresses key challenges in vascular complications of liver disease, including the management of portal vein thrombosis (PVT) in patients with and without cirrhosis. Experts will explore controversies surrounding long-term anticoagulation therapy and discuss insights from the CIRROXABAN paper. Additionally, the episode will shed light on the management of splanchnic artery aneurysms, offering valuable guidance for clinical practice.Moderator:  Pierre-Emmanuel Rautou;Faculty: Sarwa Darwish Murad, Juan-Carlos Garcia-Pagan, Valérie Vilgrain Related episodesS4E11 – YI Choice: Gene therapy for liver disease — RNA interference and beyondS4E6 – Regenerating the liver graft with a machine?S3E11 – Regenerative Hepatology: From stem cells to tissue engineeringS2E9 – YI Choice: Propelling liver cell biology into the third dimensionAll EASL Studio Podcasts are available on EASL Campus.Click here to see all EASL Video Podcasts on Apple Podcasts.

This EASL Studio episode explores state-of-the-art practices in diagnosing steatotic liver disease and stratifying patients effectively for targeted treatment in 2025. Focusing on integrating cardiometabolic risk profiling and dynamic alcohol consumption assessment, the discussion will discuss contemporary methods, frequency, and practical implementation in clinical settings to enhance precision medicine approaches.Moderator: Aleksander Krag Faculty: Meena Bansal, Mattias Ekstedt, Arun Sanyal All EASL Studio Podcasts are available on EASL Campus.Click here to see all EASL Video Podcasts on Apple Podcasts.

With the release of the new HBV guidelines, treatment eligibility broadens. This EASL Studio explores how to communicate these changes, support shared decision-making, ensure adherence, and engage patients in ongoing care and clinical trials.Moderator: Ahmed Elsharkawy Faculty: Markus Cornberg, Sital Shah, Thomas Tu, Su WangThis EASL Studio is supported by Aligos Therapeutics, GSK and Gilead Sciences Europe Ltd . EASL has received no input from Aligos Therapeutics, GSK or Gilead Sciences Europe Ltd with regards to the content of this programme.All EASL Studio Podcasts are available on EASL Campus.Click here to see all EASL Video Podcasts on Apple Podcasts.